NCT00687674 - Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

dexamethasone

20 mg orally Days 1, 8, 15, 22 of 28 day cycle

DRUG

sorafenib tosylate

Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression

DRUG

Lenalidomide

Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression

Trial Locations (1)

55905

Mayo Clinic, Rochester